Published in Eur J Health Econ on September 01, 2006
Future MS care: a consensus statement of the MS in the 21st Century Steering Group. J Neurol (2012) 0.83
Cost of Illness of Multiple Sclerosis - A Systematic Review. PLoS One (2016) 0.80
Multiple sclerosis: relapses, resource use, and costs. Eur J Health Econ (2015) 0.76
Assessing cost-effectiveness in the management of multiple sclerosis. Clinicoecon Outcomes Res (2009) 0.75
Differences in utility scores obtained through Brazilian and UK value sets: a cross-sectional study. Health Qual Life Outcomes (2015) 0.75
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol (2009) 3.91
The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol (2013) 3.13
Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology (2006) 2.72
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation (2011) 2.35
Effectiveness of a novel integrative online treatment for depression (Deprexis): randomized controlled trial. J Med Internet Res (2009) 2.34
MYO5B mutations cause microvillus inclusion disease and disrupt epithelial cell polarity. Nat Genet (2008) 2.24
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace (2008) 1.68
Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One (2010) 1.68
Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychother Psychosom (2014) 1.64
Atrial noninvasive activation mapping of paced rhythm data. J Cardiovasc Electrophysiol (2003) 1.60
Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries. Europace (2010) 1.59
Comparison of the specificity of implantable dual chamber defibrillator detection algorithms. Pacing Clin Electrophysiol (2004) 1.46
Long-term results of high vs. normal impedance ventricular leads on actual (Real-Life) pacemaker generator longevity. Europace (2008) 1.45
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol (2012) 1.43
Clinical predictors of health-related quality of life after pacemaker implantation. Wien Klin Wochenschr (2006) 1.43
Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol (2010) 1.37
Role of DNA repair by nonhomologous-end joining in Bacillus subtilis spore resistance to extreme dryness, mono- and polychromatic UV, and ionizing radiation. J Bacteriol (2007) 1.33
Model-based imaging of cardiac electrical excitation in humans. IEEE Trans Med Imaging (2002) 1.30
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol (2013) 1.27
Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum (2002) 1.26
What makes Internet therapy work? Cogn Behav Ther (2009) 1.25
Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells. Mol Endocrinol (2005) 1.25
Pregnancy and birth outcomes of women with intellectual disability in Sweden: a national register study. Acta Obstet Gynecol Scand (2012) 1.23
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler (2013) 1.22
A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions. Brain (2003) 1.18
Newborns of mothers with intellectual disability have a higher risk of perinatal death and being small for gestational age. Acta Obstet Gynecol Scand (2012) 1.15
Activation of Akt (PKB) and suppression of FKHRL1 in mouse and rat oocytes by stem cell factor during follicular activation and development. Dev Biol (2005) 1.14
Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One (2008) 1.14
HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis (2004) 1.13
Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation. Gene (2004) 1.13
Astronaut's organ doses inferred from measurements in a human phantom outside the international space station. Radiat Res (2009) 1.09
TLR9 cooperates with TLR4 to increase IL-12 release by murine dendritic cells. Mol Immunol (2007) 1.08
Thalamic network oscillations synchronize ontogenetic columns in the newborn rat barrel cortex. Cereb Cortex (2012) 1.07
Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ (2006) 1.07
Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ (2006) 1.05
Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ (2006) 1.05
Antibodies as biological markers for pathophysiological processes in MS. J Neuroimmunol (2006) 1.01
The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. Eur J Cardiovasc Prev Rehabil (2004) 1.00
Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases). Clin Immunol (2004) 0.99
Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders. J Neuroimmunol (2011) 0.99
Homogeneous distribution of large-conductance calcium-dependent potassium channels on soma and apical dendrite of rat neocortical layer 5 pyramidal neurons. Eur J Neurosci (2005) 0.96
Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol (2003) 0.96
Analysis of multiple sclerosis lesions using a fusion of 3.0 T FLAIR and 7.0 T SWI phase: FLAIR SWI. J Magn Reson Imaging (2011) 0.95
Factors determining utility measured with the EQ-5D in patients with atrial fibrillation. Qual Life Res (2010) 0.95
Preterm birth in Sweden: what are the average lengths of hospital stay and the associated inpatient costs? Acta Paediatr (2006) 0.94
The MATROSHKA facility--dose determination during an EVA. Radiat Prot Dosimetry (2006) 0.94
Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosis. J Neuroimmunol (2005) 0.94
Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients. Clin Cardiol (2011) 0.94
Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord (2011) 0.94
Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis. Eur J Health Econ (2006) 0.94
Advancing psychotherapy and evidence-based psychological interventions. Int J Methods Psychiatr Res (2014) 0.93
Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. J Neurol (2006) 0.93
Is there a causal link between maltreatment and adolescent pregnancy? A literature review. Perspect Sex Reprod Health (2002) 0.93
Large-conductance calcium-dependent potassium channels prevent dendritic excitability in neocortical pyramidal neurons. Pflugers Arch (2008) 0.92
Long term health care consumption and cost expenditure in systolic heart failure. Eur J Intern Med (2012) 0.92
The EVIDENT-trial: protocol and rationale of a multicenter randomized controlled trial testing the effectiveness of an online-based psychological intervention. BMC Psychiatry (2013) 0.91
Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ (2006) 0.90
Persistent activity in layer 5 pyramidal neurons following cholinergic activation of mouse primary cortices. Eur J Neurosci (2011) 0.89
Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people. PLoS One (2013) 0.89
Does a pre-treatment diagnostic interview affect the outcome of internet-based self-help for social anxiety disorder? a randomized controlled trial. Behav Cogn Psychother (2012) 0.89
Therapist factors in Internet-delivered cognitive behavioural therapy for major depressive disorder. Cogn Behav Ther (2009) 0.88
Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurol (2013) 0.88
Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Health Econ (2006) 0.88
Natalizumab treatment reduces endothelial activity in MS patients. J Neuroimmunol (2010) 0.88
New efficient stimuli for evoking frequency-specific auditory steady-state responses. J Am Acad Audiol (2006) 0.87
Costs and quality of life of multiple sclerosis in Switzerland. Eur J Health Econ (2006) 0.87
Information and knowledge about Down syndrome among women and partners after first trimester combined testing. Acta Obstet Gynecol Scand (2015) 0.87
HLA-B8 association with late-stage melanoma--an immunological lesson? BMC Med (2006) 0.87
Antimyelin antibodies with no progression to multiple sclerosis. N Engl J Med (2007) 0.86
The Golden Agers and Tick-borne encephalitis. Conference report and position paper of the International Scientific Working Group on Tick-borne encephalitis. Wien Med Wochenschr (2005) 0.86
The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden. Eur J Cardiovasc Prev Rehabil (2009) 0.86
Costs and quality of life in multiple sclerosis in The Netherlands. Eur J Health Econ (2006) 0.86
Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol (2007) 0.86
Increased incidence of malignancies in Sweden after the Chernobyl accident--a promoting effect? Am J Ind Med (2006) 0.86
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med (2013) 0.86
Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: Influence of relapses and immunomodulatory treatments. J Neuroimmunol (2006) 0.85
Internet-based individually versus group guided self-help treatment for social anxiety disorder: protocol of a randomized controlled trial. BMC Psychiatry (2014) 0.84
Efficacy of a neuropsychological training programme for patients with multiple sclerosis -- a randomised controlled trial. Wien Klin Wochenschr (2005) 0.84
Patient expectations in internet-based self-help for social anxiety. Cogn Behav Ther (2013) 0.83
IR-spectrophotoelectrochemical characterization of mesoporous semiconductor films. Anal Chem (2012) 0.83
Facts first, then reaction--expectant fathers' experiences of an ultrasound screening identifying soft markers. Midwifery (2011) 0.83
Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland. Clin Ther (2012) 0.82
Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. Mult Scler (2011) 0.82
Neonatal kyphectomy in the patient with myelomeningocele. Spine (Phila Pa 1976) (2003) 0.82
Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae, human papillomavirus, and polyomavirus are not detectable in human tissue with epithelial ovarian cancer, borderline tumor, or benign conditions. Am J Obstet Gynecol (2009) 0.82
Increased serum levels of soluble CD14 indicate stable multiple sclerosis. J Neuroimmunol (2006) 0.82
Carbon-ion-induced activation of the NF-κB pathway. Radiat Res (2011) 0.82